secwatch / observer
MIRM Mirum Pharmaceuticals, Inc.
CIK 0001759425 50 ready 8-Ks latest August 5, 2026, 4:02 PM ET RSS · JSON
Activity: NORMAL 1 filings / 30d vs 1 baseline
Ready 8-Ks 50
Latest filing August 5, 2026, 4:02 PM ET
Top materiality 1.00
Event mix earnings ×19 · other_material ×9 · m_and_a ×7
Sentiment 29 pos · 5 neg · 16 neu
Latest earnings reported 2026-Q1
Executive change recent →
SHENANIGAN SCORE 1 / 7 see the board

Recent 8-K filings for MIRM

Highest-materiality recent filing

Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M

December 8, 2025, 6:59 PM ET M&A materiality 1.00 positive item 1.01item 3.02item 7.01item 8.01item 9.01 ◈ Material Agreements

Read filing →

Executive changes

Role change

Peter Radovich

President
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2024-01-16
Filed
January 16, 2024, 6:59 PM ET
On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.
Role change

Christopher Peetz

Chief Executive Officer
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2024-01-16
Successor
Peter Radovich
Filed
January 16, 2024, 6:59 PM ET
On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.
Appointed

Eric Bjerkholt

Chief Financial Officer
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2023-09-11
Filed
September 11, 2023, 7:59 PM ET
On September 11, 2023, Mirum Pharmaceuticals, Inc., (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Eric Bjerkholt as the Chief Financial Officer of the Company, including as the “principal financial officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective September 11, 2023 (the “Appointment Date”).
Departed

Niall O'Donnell

Director
MIRM · Mirum Pharmaceuticals, Inc.
Filed
April 6, 2023, 7:59 PM ET
On April 5, 2023, Niall O’Donnell, Ph.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.
Appointed

Timothy Walbert

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2023-04-05
Filed
April 6, 2023, 7:59 PM ET
On April 5, 2023, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Timothy Walbert to the Board, effective immediately.
Departed

Ian Clements

Chief Financial Officer
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2023-05-15
Filed
January 9, 2023, 6:59 PM ET
Dr. Clements will resign as Chief Financial Officer of the Company.
Departed

Carol L. Brosgart

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2022-12-19
Successor
Lon Cardon
Filed
December 19, 2022, 6:59 PM ET
On December 16, 2022, Carol L. Brosgart, M.D., notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company and as a member of the Nominating and Corporate Governance Committee of the Board, effective December 19, 2022.
Appointed

Lon Cardon

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2022-12-19
Filed
December 19, 2022, 6:59 PM ET
On December 19, 2022, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Lon Cardon, Ph.D., FMedSci, to the Board, effective immediately.
Departed

Edward T. Mathers

director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2022-09-01
Filed
September 2, 2022, 7:59 PM ET
On September 1, 2022, Edward T. Mathers notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of his resignation as a director of the Company and as a member of the Compensation Committee of the Board, effective September 1, 2022.
Appointed

Saira Ramasastry

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2022-06-02
Filed
June 6, 2022, 7:59 PM ET
On June 2, 2022, the Board of Directors (the "Board") of Mirum Pharmaceuticals, Inc. (the "Company"), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Saira Ramasastry to the Board, effective immediately.
Departed

Tiba Aynechi

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2021-08-19
Filed
August 20, 2021, 7:59 PM ET
On August 16, 2021, Tiba Aynechi, Ph.D. notified the board of directors (the “Board”) of Mirum Pharmaceuticals, Inc. (the “Company”) of her resignation as a director of the Company, effective August 19, 2021.
Appointed

William Fairey

Director
MIRM · Mirum Pharmaceuticals, Inc.
Effective
2021-08-19
Filed
August 20, 2021, 7:59 PM ET
On August 19, 2021, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed William Fairey to the Board, effective immediately.

Earnings & guidance

2026-Q1 EPS reported -$13.43 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.75 · Most common event earnings

29 positive 5 negative 16 neutral

source · MIRM on sec.gov